- Amgen Inc. - The company offers epidermal growth factor receptor that provides medications which include Aimovig injection, Arnasep, Avsola, Blincyto, Corlanor, Lumacars, and many more, under the brand name of Amgen Inc.
- Apollomics Inc. - The company offers epidermal growth factor receptor that provides tumor inhibitors, chemotherapy, and immuno-oncology drugs for cancer patients.
- AstraZeneca Plc - The company offers epidermal growth factor receptor that provides therapy for oncology, biopharmaceuticals, cardiovascular, renal and metabolism, respiratory, and immunology, under the brand name of AstraZeneca Plc.
- Boehringer Ingelheim International GmbH - The company offers epidermal growth factor receptor that provides medications and therapy for heart disease, cancer, lung disease, mental disease, skin disease, and retinal disease.
- Bristol Myers Squibb Co. - The company operates in a single segment and is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines for various diseases.
- To know about all major vendor offerings - Request a sample report
Read the 120-page report with TOC on "Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis Report by Geography (North America, Europe, Asia, and Rest of World (ROW)) and Market Landscape (lung cancer, colorectal cancer, breast cancer, and others), and the Segment Forecasts, 2022-2026". Gain competitive intelligence about market leaders. Track key industry opportunities, trends, and threats. Information on marketing, brand, strategy and market development, sales, and supply functions. https://www.technavio.com/report/report/epidermal-growth-factor-receptor-egfr-inhibitors-market-industry-analysis
Get ready to achieve excellent business outcomes from this exclusive Epidermal Growth Factor Receptor (EGFR) Inhibitor Market report by Technavio. The report will include highlights of the overall market which includes frequently asked questions such as -
- What are historical revenue figures and estimated revenue figures as well as CAGR during the forecast timeframe?
- What is the current trend taking place in the market space?
- Which are business tactics that will influence competitive scenarios along with defining the growth potential of the market?
- What are market drivers, restraints, and challenges impacting demand & growth of the market?
- Which regions & segments will garner massive revenue and emerge as market leaders in upcoming years?
The competitive scenario provided in the Epidermal Growth Factor Receptor (EGFR) Inhibitor Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Don't wait, make a strategic approach & boost your business goals with our Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Forecast Report - Buy Now!
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market: Drivers & Challenges
The key factor driving the global epidermal growth factor receptor (EGFR) inhibitors market growth is the strong prevalence of major cancer indications. The US reports the highest number of cancer cases in the world. According to the Union for International Cancer Control (UICC), there were 19.1 million cancer cases in 2020, which resulted in 10 million deaths globally. In addition, the number of breast cancer cases increased by 24% in 2020 when compared with 2019. Moreover, the International Agency for Research on Cancer (IARC) has estimated that there will be around 29.4 million cancer cases by 2040, which will result in the death of 16.4 million people due to cancer. Despite the increasing prevalence of cancer, the market still witnesses a huge unmet need, which has created an opportunity for vendors to conduct a study on drugs such as EGFR inhibitors for the treatment of cancer indications. Such factors are expected to support the market growth during the forecast period.
However, one of the key challenges to the global epidermal growth factor receptor (EGFR) inhibitors market growth is the high treatment costs. For instance, the treatment using IRESSA, a novel EGFR inhibitor by AstraZeneca, is priced at approximately USD 8100 for a supply of 30 tablets. Similarly, the yearly cost of treatment using TAGRISSO by AstraZeneca is approximately USD 13,000 per month or USD 156,000 per year for the treatment of NSCLC. ERBITUX, a novel EGFR inhibitor by Eli Lilly and Company, is priced at approximately USD 80,000 for 18 weeks of treatment for head and neck cancer, and colorectal cancer, making the treatment cost up to USD 235,000 per year. Drugs such as TYKERB by Novartis and TARCEVA by Roche are also priced on the higher end, with the yearly treatment costs going as high as USD 30,000. Thus, the high cost of the approved EGFR inhibitors is expected to hinder the growth of the global EGFR inhibitors market during the forecast period.
To know about other drivers & challenges - Click Now!
Epidermal Growth Factor Receptor (EGFR) Inhibitors Market: Segmentation Analysis
Geography Outlook (Revenue, USD bn, 2021-2026)
- North America - size and forecast 2021-2026
- Europe - size and forecast 2021-2026
- Asia - size and forecast 2021-2026
- Rest of World (ROW) - size and forecast 2021-2026
Landscape Outlook (Revenue, USD bn, 2021-2026)
- Lung cancer - size and forecast 2021-2026
- Colorectal cancer - size and forecast 2021-2026
- Breast cancer - size and forecast 2021-2026
- Others - size and forecast 2021-2026
To know about the contribution of each segment - Grab an Exclusive Sample Report
Related Reports:
- The breast implant market size is expected to reach a value of USD 437.17 million at a CAGR of 5.80% from 2020 to 2025.
- The orthopedic 3D printing devices market share is expected to increase by USD 901.59 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 15.61%.
Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.6% |
Market growth 2022-2026 |
USD 6.75 billion |
Market structure |
Fragmented |
YoY growth (%) |
8.0 |
Performing market contribution |
North America at 43% |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Amgen Inc., Apollomics Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., and Takeda Pharmaceutical Co. Ltd. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Content
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Indication
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Indication
- 5.1 Market segments
- Exhibit 24: Chart on Indication - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Indication - Market share 2021-2026 (%)
- 5.2 Comparison by Indication
- Exhibit 26: Chart on Comparison by Indication
- Exhibit 27: Data Table on Comparison by Indication
- 5.3 Lung cancer - Market size and forecast 2021-2026
- Exhibit 28: Chart on Lung cancer - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Lung cancer - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Lung cancer - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Lung cancer - Year-over-year growth 2021-2026 (%)
- 5.4 Colorectal cancer - Market size and forecast 2021-2026
- Exhibit 32: Chart on Colorectal cancer - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Colorectal cancer - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Colorectal cancer - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Colorectal cancer - Year-over-year growth 2021-2026 (%)
- 5.5 Breast cancer - Market size and forecast 2021-2026
- Exhibit 36: Chart on Breast cancer - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Breast cancer - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Breast cancer - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Breast cancer - Year-over-year growth 2021-2026 (%)
- 5.6 Others - Market size and forecast 2021-2026
- Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
- Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
- Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
- Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)
- 5.7 Market opportunity by Indication
- Exhibit 44: Market opportunity by Indication ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 46: Chart on Market share by geography 2021-2026 (%)
- Exhibit 47: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 48: Chart on Geographic comparison
- Exhibit 49: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 France - Market size and forecast 2021-2026
- Exhibit 82: Chart on France - Market size and forecast 2021-2026 ($ million)
- Exhibit 83: Data Table on France - Market size and forecast 2021-2026 ($ million)
- Exhibit 84: Chart on France - Year-over-year growth 2021-2026 (%)
- Exhibit 85: Data Table on France - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 86: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 87: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 88: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 89: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 90: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 91: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 92: Matrix on vendor position and classification
- 10.3 Amgen Inc.
- Exhibit 93: Amgen Inc. - Overview
- Exhibit 94: Amgen Inc. - Product / Service
- Exhibit 95: Amgen Inc. - Key offerings
- 10.4 Apollomics Inc.
- Exhibit 96: Apollomics Inc. - Overview
- Exhibit 97: Apollomics Inc. - Product / Service
- Exhibit 98: Apollomics Inc. - Key news
- Exhibit 99: Apollomics Inc. - Key offerings
- 10.5 AstraZeneca Plc
- Exhibit 100: AstraZeneca Plc - Overview
- Exhibit 101: AstraZeneca Plc - Product / Service
- Exhibit 102: AstraZeneca Plc - Key news
- Exhibit 103: AstraZeneca Plc - Key offerings
- 10.6 Boehringer Ingelheim International GmbH
- Exhibit 104: Boehringer Ingelheim International GmbH - Overview
- Exhibit 105: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 106: Boehringer Ingelheim International GmbH - Key news
- Exhibit 107: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 108: Boehringer Ingelheim International GmbH - Segment focus
- 10.7 Checkpoint Therapeutics Inc.
- Exhibit 109: Checkpoint Therapeutics Inc. - Overview
- Exhibit 110: Checkpoint Therapeutics Inc. - Business segments
- Exhibit 111: Checkpoint Therapeutics Inc. - Key offerings
- Exhibit 112: Checkpoint Therapeutics Inc. - Segment focus
- 10.8 Eli Lilly and Co.
- Exhibit 113: Eli Lilly and Co. - Overview
- Exhibit 114: Eli Lilly and Co. - Business segments
- Exhibit 115: Eli Lilly and Co. - Key offerings
- Exhibit 116: Eli Lilly and Co. - Segment focus
- 10.9 F. Hoffmann La Roche Ltd.
- Exhibit 117: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 118: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 119: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 120: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 121: F. Hoffmann La Roche Ltd. - Segment focus
- 10.10 Novartis AG
- Exhibit 122: Novartis AG - Overview
- Exhibit 123: Novartis AG - Business segments
- Exhibit 124: Novartis AG - Key offerings
- Exhibit 125: Novartis AG - Segment focus
- 10.11 Pfizer Inc.
- Exhibit 126: Pfizer Inc. - Overview
- Exhibit 127: Pfizer Inc. - Product / Service
- Exhibit 128: Pfizer Inc. - Key news
- Exhibit 129: Pfizer Inc. - Key offerings
- 10.12 Puma Biotechnology Inc.
- Exhibit 130: Puma Biotechnology Inc. - Overview
- Exhibit 131: Puma Biotechnology Inc. - Business segments
- Exhibit 132: Puma Biotechnology Inc. - Key news
- Exhibit 133: Puma Biotechnology Inc. - Key offerings
- Exhibit 134: Puma Biotechnology Inc. - Segment focus
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 135: Inclusions checklist
- Exhibit 136: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 137: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 138: Research methodology
- Exhibit 139: Validation techniques employed for market sizing
- Exhibit 140: Information sources
- 11.5 List of abbreviations
- Exhibit 141: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article